Research library
Investment research, in the open.
Research on companies, industries and markets, grounded in official filings and updated as new findings arrive. Free to read.
Recently updated
industry · United States
Aviation Network Outages and Operating Leverage: Margin Risk Analysis
Large-scale aviation ground stops compress airline margins through lost passenger revenue and non-fuel cost surges from passenger duty-of-care reimbursements and stranded flight crews. Historical precedent demonstrates significant operating leverage; Delta Air Lines absorbed a $550 million pre-tax operating profit hit from approximately 7,000 cancellations over a five-day disruption. Disruption expenses also cause CASM ex-fuel to spike sharply, quickly turning marginal quarterly profits into losses for thin-margin or unprofitable carriers.
Updated 2026-11-14
industry · United States
Rare Disease Biopharma M&A: Navigating the 2028 Patent Cliff
Large pharmaceutical operators face a major patent expiration cliff centered around 2028, highlighted by loss of exclusivity for blockbusters such as Merck's Keytruda. Rare disease biotechnology companies offer durable, high-margin revenue and long regulatory exclusivity to backfill revenue losses. Companies with de-risked commercial portfolios, self-funded cash flows, or strong balance sheets—such as Catalyst Pharmaceuticals, Ultragenyx, and Moderna—represent viable acquisition and partnership candidates.
Updated 2026-11-12
industry · United States
Undervalued Global Therapeutics and Pharmaceuticals: Deep-Value Clinical and Commercial Assets
This research analyzes public therapeutics and biopharmaceutical companies facing a structural patent cliff and shifting M&A landscape. By screening for Phase 2 proof-of-concept, adequate liquidity, and durable IP moats, it reviews opportunities such as Eton Pharmaceuticals, Biohaven, Genmab, Revolution Medicines, Amgen, and Ultragenyx. The analysis highlights Eton Pharmaceuticals as a disciplined orphan drug acquirer with positive operating cash flow and lower clinical binary risk.
Updated 2026-11-12
industry · United States
Custom ASIC Packaging Risk Allocation: Broadcom vs. Alphabet
Alphabet absorbs the primary take-or-pay and underutilization risk for TSMC's CoWoS packaging capacity rather than Broadcom. Broadcom operates on a back-to-back purchase order basis without long-term minimum commitments, passing liability for committed work-in-process and cancellation fees directly to Alphabet. This contrasts sharply with merchant semiconductor models where chip designers absorb massive balance-sheet supply obligations.
Updated 2026-11-12
industry · Taiwan
Hyperscaler Custom ASICs vs. AMD: Absorbing TSMC CoWoS Packaging Capacity
Hyperscaler custom ASICs are structurally and financially better positioned than AMD to absorb TSMC's spare CoWoS capacity due to captive internal deployment and balance-sheet scale. However, neither hyperscalers nor AMD can fill vacated packaging capacity immediately due to front-end wafer fabrication lead times of three to five months and multi-quarter commitments for high-bandwidth memory (HBM). Over a 6- to 12-month horizon, hyperscaler ASICs represent the most credible pipeline to capture displaced packaging lines.
Updated 2026-11-12
industry · Taiwan
TSMC Advanced Packaging Fungibility: Investment Research
TSMC cannot quickly reallocate CoWoS capacity from Nvidia to AMD due to architectural differences between packaging variants like CoWoS-S and CoWoS-L, along with multi-quarter retooling lead times. Reallocation is further constrained by the requirement for matched front-end logic wafers and dedicated HBM stacks, as well as multi-year binding take-or-pay capacity agreements. In an AI hardware spending digestion phase, shared hyperscaler end-demand and volume disparities make it unlikely that AMD could absorb excess packaging capacity, resulting in lower line utilization rather than frictionless reallocation.
Updated 2026-11-12